The 3 most recent market catalysts affecting $ENGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 92
enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate
enGene Holdings (ENGN) announced a Q3 EPS of $(0.47), which was worse than the analyst consensus estimate of $(0.43). This 9.3% miss indicates that the company's financial performa…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 75
enGene Therapeutics Announces Virtual Key Opinion Leader Event On August 11 Covering NMIBC Treatment Landscape, Sequencing, Pricing And Reimbursement Dynamics
This event is a significant corporate catalyst for enGene Therapeutics (ENGN) as it directly addresses crucial commercial aspects of its NMIBC treatment. The discussion around trea…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 60
EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman
EnGene Therapeutics (ENGN) announced a significant change in its board leadership, appointing Michael Heffernan as the new Chairman, replacing Richard Glickman. This move is presen…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.